secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-007055
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD
--------------------------------------------------------------------------------

- Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.
- Cash and marketable securities $161.4M at March 31, 2024; expects lower quarterly cash burn ahead.
- Progressing ATI-2138 (ITK/JAK3 inhibitor) into Phase 2a proof-of-concept trial for moderate-to-severe atopic dermatitis.
- Seeking global development partner for lepzacitinib (topical JAK 1/3 inhibitor) after positive Phase 2b AD data.
- R&D expenses fell to $9.8M from $22.6M, driven by wind-down of programs and workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/0001558370-24-007055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/acrs-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer